NMPA (China) approves Verkazia to treat vernal keratoconjunctivitis (VKC) in children and adolescents.- Santen
China’s National Medical Products Administration (NMPA) granted the approval to the company’s local subsidiary. Santen plans to launch the drug by the end of March next year. VKC is a rare and recurrent allergic eye condition, most common in children and adolescents, which causes severe inflammation of the ocular surface. It is characterized by symptoms like intense itching, painful eyes, and light sensitivity.
Related news and insights
Novavax is awaiting US emergency use authorization for its prototype COVID-19 vaccine and is committed to bringing it to market. Clinical data generated to-date demonstrate that this prototype vaccine offers broad immune responses including against circulating variants, such as the Omicron BA.4/5.